Fig 4.TIF (590.92 kB)

Prevalence of signature RASs in NS5A in terms of reasons for treatment failure.

Download (590.92 kB)
figure
posted on 24.10.2016 by Jun Itakura, Masayuki Kurosaki, Chitomi Hasebe, Yukio Osaki, Kouji Joko, Hitoshi Yagisawa, Shinya Sakita, Hiroaki Okushin, Takashi Satou, Hiroyuki Hisai, Takehiko Abe, Keiji Tsuji, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Yasushi Ide, Chikara Ogawa, Syotaro Tsuruta, Kouichi Takaguchi, Miyako Murakawa, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi

The prevalence of signature RAS at L31 and/or Y93 in NS5A in patients who stopped the therapy by adverse events was significantly low than others.

History

Licence

Exports